NCT05827757

Evaluating the Safety and Efficacy of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Transplantation on Proinflammatory Cytokines and Anti-inflammatory Cytokines on Ageing-related Low-grade Inflammation Patients.

Single-group, Open-label, Phase I / II Clinical Trial: Evaluating the Safety and Efficacy of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Transplantation on Proinflammatory Cytokines and Cytokines Balance in Inflammaging (Ageing-related Low-grade Inflammation) Patients.

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: DNA International Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

Single-group, open-label, phase I / II clinical trial: Evaluation of the safety of autologous adipose tissue-derived mesenchymal stem cell transplantation in inflammaging (Ageing-related low-grade inflammation) patients.

Detailed description

The proposed study is a single-group, open-label, phase I / II clinical trial in which the patients will be treated with two doses (100 million i.v) of autologous adipose tissue-derived mesenchymal stem cell transplantation. This study aims to evaluate the safety and efficiency of autologous adipose tissue-derived mesenchymal stem cell transplantation in inflammaging (Ageing-related low-grade inflammation) patients. The inflammaging-patients are who have cytokine increasing (IL6 and TNF alfa)

Conditions

• Aging Problems
• Aging
• Chronic Inflammation

Interventions

Type	Name	Description
BIOLOGICAL	autologous adipose-derived mesenchymal stem cell transplantation	Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90

Timeline

• Start date: 2020-04-28
• Primary completion: 2025-04-13
• Completion: 2025-04-13
• First posted: 2023-04-25
• Last updated: 2023-10-04

Locations

1 site across 1 country: Vietnam